Literature DB >> 28350861

Efficacy and effects on cardiac function of radiofrequency catheter ablation vs. direct current cardioversion of persistent atrial fibrillation with left ventricular systolic dysfunction.

Maojing Wang1, Shanglang Cai1, Wei Ding2, Yujie Deng1, Qing Zhao1.   

Abstract

OBJECTIVE: To evaluate the effect of catheter ablation vs. direct current synchronized cardioversion (DCC) in patients with persistent atrial fibrillation (AF) and left ventricular systolic dysfunction, and to define baseline features of patients that will get more benefit from ablation.
METHODS: From July 2013 to October 2014, 97 consecutive single-center patients with persistent AF and symptomatic heart failure (left ventricular ejection fraction (LVEF) <50%) underwent DCC followed by amiodarone (n = 40) or circumferential pulmonary vein isolation (PVI; n = 57) according to patient's preference were recruited in the study. Post-ablation recurrence was treated with atrial roof and mitral isthmus lines ablation with or without PVI based on restoration or not of pulmonary vein (PV) potential conduction. Study outcomes were 12-month rate of sustained sinus rhythm (SR) and cardiac function. Baseline characteristics were compared between patients with and without cardiac function improvement post ablation.
RESULTS: With similarly distributed characteristics at baseline, ablation (mean 1.8 procedures) relative to DCC yielded significantly higher level of 12-month SR maintenance rate (68.42% vs. 35%, P = 0.001); and better LVEF and New York Heart Association class. with significant effect for DCC only in maintained SR cases. Post ablation LVEF increased (>20% or to over 55%) in 31 (54.39%) patients with worse baseline cardiac function and ventricular rate control.
CONCLUSIONS: Catheter ablation relative to cardioversion of persistent AF with symptomatic heart failure yielded better 12-month SR maintenance and cardiac function. Compared with non-responders, patients with improved LVEF post-ablation had poorer ventricular rate control and cardiac function at baseline, suggesting a significant component of tachycardia-induced cardiomyopathy in this group.

Entities:  

Mesh:

Year:  2017        PMID: 28350861      PMCID: PMC5370131          DOI: 10.1371/journal.pone.0174510

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  25 in total

Review 1.  The effects of amiodarone on the thyroid.

Authors:  E Martino; L Bartalena; F Bogazzi; L E Braverman
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  How to perform linear lesions.

Authors:  Pierre Jaïs; Mélèze Hocini; Mark D O'Neill; George J Klein; Sébastien Knecht; Matsuo Sheiiro; Leonardo Arentes; Sathish Kodali; Jacques Clémenty; Michel Haïssaguerre
Journal:  Heart Rhythm       Date:  2007-01-21       Impact factor: 6.343

Review 3.  Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation.

Authors:  Kevin M Trulock; Sanjiv M Narayan; Jonathan P Piccini
Journal:  J Am Coll Cardiol       Date:  2014-08-19       Impact factor: 24.094

4.  Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.

Authors:  Riccardo Cappato; Hugh Calkins; Shih-Ann Chen; Wyn Davies; Yoshito Iesaka; Jonathan Kalman; You-Ho Kim; George Klein; Andrea Natale; Douglas Packer; Allan Skanes; Federico Ambrogi; Elia Biganzoli
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-12-07

5.  Reversion of tachycardiomyopathy after beta-blocker.

Authors:  M P van den Berg; D J van Veldhuisen; H J Crijns; K I Lie
Journal:  Lancet       Date:  1993-06-26       Impact factor: 79.321

6.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

7.  Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry).

Authors:  Gregory Y H Lip; Cécile Laroche; Popescu Mircea Ioachim; Lars Hvilsted Rasmussen; Laura Vitali-Serdoz; Lucian Petrescu; Dan Darabantiu; Harry J G M Crijns; Paulus Kirchhof; Panos Vardas; Luigi Tavazzi; Aldo P Maggioni; Giuseppe Boriani
Journal:  Eur Heart J       Date:  2014-08-31       Impact factor: 29.983

8.  Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study.

Authors:  S M Vaziri; M G Larson; E J Benjamin; D Levy
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

9.  Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation.

Authors:  Feifan Ouyang; Dietmar Bänsch; Sabine Ernst; Anselm Schaumann; Hitoshi Hachiya; Minglong Chen; Julian Chun; Peter Falk; Afsaneh Khanedani; Matthias Antz; Karl-Heinz Kuck
Journal:  Circulation       Date:  2004-10-04       Impact factor: 29.690

10.  A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.

Authors:  David G Jones; Shouvik K Haldar; Wajid Hussain; Rakesh Sharma; Darrel P Francis; Shelley L Rahman-Haley; Theresa A McDonagh; S Richard Underwood; Vias Markides; Tom Wong
Journal:  J Am Coll Cardiol       Date:  2013-03-07       Impact factor: 24.094

View more
  2 in total

Review 1.  Invasive therapies for patients with concomitant heart failure and atrial fibrillation.

Authors:  Wei Wei; Michael Shehata; Xunzhang Wang; Fang Rao; Xianzhan Zhan; Huiming Guo; Xianhong Fang; Hongtao Liao; Jian Liu; Hai Deng; Yang Liu; Yumei Xue; Shulin Wu
Journal:  Heart Fail Rev       Date:  2019-09       Impact factor: 4.214

2.  Predictors of arrhythmia recurrence in patients with heart failure undergoing left atrial ablation for atrial fibrillation.

Authors:  George Bazoukis; Konstantinos P Letsas; Gary Tse; Katerina K Naka; Panagiotis Korantzopoulos; Evangelia Ntzani; Konstantinos Vlachos; Athanasios Saplaouras; Eirini Pagkalidou; Lampros K Michalis; Antonios Sideris; Michael Efremidis
Journal:  Clin Cardiol       Date:  2018-01-22       Impact factor: 2.882

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.